Analysts await Opexa Therapeutics, Inc. (NASDAQ:OPXA) to report earnings on Mar, 15 for the fiscal quarter ending Dec 2015.

They expect $-0.6 EPS, up 60% or $0.36 from last year’s $-0.96 per share.

At the moment 4 analysts are watching Opexa Therapeutics, Inc. (NASDAQ:OPXA), 0 rate it “Buy”, 4 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 3 analysts have a mean sales target of 0.51 million. For the quarter ending Jun-16, 3 analysts have a mean sales target of 0.51 million whilst for the year ending Dec-16, 5 analysts have a mean target of 7.40 million.

In terms of earnings per share, 3 analysts have a -0.44 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 3 analysts have a -0.40 EPS mean target and for the quarter ending Jun-16 there are 5 estimates of -1.37 EPS.

Total shares held by institutions as of the most recent company filings are 359,392 with a reported 40,985 bought and 0 sold. These holdings make up 1.37% of the company’s outstanding shares.

The stock decreased 4.39% or $0.09 during the last trading session, hitting $80.00. Opexa Therapeutics, Inc. (NASDAQ:OPXA) has risen 95.2% over the past 6 months and is uptrending.